SYNTHESIS OF ZIRCONIUM OXIDE CATALYST SUPPORTED ON CARBONIZED MATERIAL FOR THE OPTIMIZATION OF BIODIESEL FROM WASTE VEGETABLE OIL
Background: In line with the current global energy crisis, there is an urgent need to seek cheap energy sources. This study has utilized waste materials for synthesizing biodiesel, an environmentally friendly alternative energy. Aim: This study aimed to prepare low-cost carbon-based zirconium impregnated heterogeneous catalysts using wood dust to produce biodiesel from waste vegetable oil (WVO). Methods: Response Surface Methodology via Central Composite Design (RSM-CCD) optimized the biodiesel production process. The physico-chemical properties of waste vegetable methyl ester were determined following the American Standard Testing of Materials (ASTM). In addition, the catalyst morphology and elemental composition were determined using Scanning Electron Microscopy (SEM) and Energy-Dispersive X-ray (EDX), respectively. Results and Discussion: The optimum conditions were observed to be 8:1 methanol/oil ratio, 5 wt% catalyst loading, 55 °C temperature, and 3 hours of reaction time. The corresponding response was observed to be 98.39%. Conclusions: The experimental analysis confirmed that the synthesized catalyst from wood dust under optimized conditions transesterified the waste vegetable oil into biodiesel with properties that comply with American Standard Testing of Materials.
Read ArticleTREATMENTS FOR ACUTE LYMPHOBLASTIC LEUKEMIA: A COMPARISON BETWEEN TISAGENLECLEUCEL AND CLOFARABINE
Background: Acute lymphoblastic leukemia (ALL) is a heterogeneous hematological malignancy predominantly affecting individuals under 20 years of age. Traditional chemotherapy, such as clofarabine, has shown efficacy; however, novel immunotherapeutic strategies like tisagenlecleucel (Kymriah®) have significantly altered the treatment paradigm. Aim: This study aimed to perform a comparative analysis of tisagenlecleucel, a CAR-T cell therapy, and clofarabine, a second-generation purine nucleoside analog, evaluating their mechanisms of action, therapeutic benefits, limitations, and clinical applicability across diverse patient populations. Methods: A systematic comparative evaluation was conducted, encompassing pharmacological characteristics, mechanisms of action, treatment protocols, efficacy, safety profiles, and clinical indications of both agents. The analysis considered pharmacokinetic and pharmacodynamic data and included patient demographic variables. Results: Tisagenlecleucel demonstrated high efficacy in refractory B-cell ALL, with durable responses and a blood half-life of 128 days, but with notable immune-related adverse effects such as cytokine release syndrome. Clofarabine, effective across a broader patient population, acts via multiple antitumor mechanisms but carries significant toxicity risks, including infection and sepsis. Discussion: The therapies present distinct clinical profiles: tisagenlecleucel offers targeted immunotherapy with high specificity but requires specialized infrastructure and management of immune toxicities. Clofarabine is more widely accessible and applicable, but is associated with conventional chemotherapy-related side effects. Treatment accessibility and cost differ markedly between the two. Conclusions: Therapy selection should be personalized based on patient-specific factors and institutional resources. Tisagenlecleucel is ideal for pediatric and young adult patients with relapsed/refractory B-cell ALL in CAR-T-capable centers, while clofarabine remains a viable option for broader ALL populations, particularly when genetic therapies are not feasible. Further research is needed to optimize therapeutic strategies and improve access to advanced treatments.
Read ArticleD-DIMER A RISK FACTOR ASSOCIATED WITH C-REACTIVE PROTEIN FOR PREDICTING THE SEVERITY OF INFECTION BY COVID-19
Background: COVID-19, caused by SARS-CoV-2, has unresolved mortality risk factors and clinical course, highlighting the need for further research. Aims: The study aimed to asses D-dimer and C-Reactive Protein (CRP) as the risk factors for severity covid-19 and who are less capable of surviving. Methods: A retrospective study conduct of COVID-19 in adult inpatients aged >20 at Al-sadder and Alamal Hospital in Iraq. Demographics, clinical trials, treatments, and viral RNA samples were analyzed. The study involved 100 patients, with 67 discharged and 33 hospitalized died. The majority of the participants 45% were aged < 40, but 55% were aged >40 years. Results: A significant and 57% were male 37(55.2%) Survivor vs. 20 (60.6%) non-survivor, p=0.024), more than 43% were female (30(44.8%) Survivor vs. 13(39.4%) non-survivor, p=0.010. Patients had underlying comorbidities (66%), survivor 37(55%), and non-survivor 29(87%). The most prominent comorbidity in non-survivors more than survivors was diabetic mellitus 85%, asthma 58%, stroke 48%, renal failure 42%, heart strake 33%, and hypertension 18%. The study found significant differences in WBC, lymphocyte count, D-dimer, Ferritin, CRP, and LDH levels in non-survivors compared to survivor patients, with a positive correlation between D- dimer and these parameters. The ROC analysis curve showed CRP with a high AUC of 80.2%, 87.9% sensitivity, and 37.3% specificity, while D-dimer and LDH had AUCs of 0.74.9 and 70%, respectively. Discussion: The study found that older age, higher d-dimer, ferritin, CRP, and LDH are associated with disease severity and higher mortality risk in adult COVID-19 patients. Conclusions: These biomarkers could aid in early detection of disease progression signs and better patient management
Read Article